⌘K
t
Solvonis Therapeutics plc announced on 03 June 2025 that the notice for its 2025 Annual General Meeting (AGM) and proxy form were posted to shareholders and submitted to the National Storage Mechanism. The AGM is scheduled to take place at 12.00 noon on 27 June 2025, at the Company's registered office, 25 Eccleston Place, London SW1W 9NF.
| Date | 3 Jun 2025 |
| Time | 16:30:00 |
| Category | AGMs and other meetings |
| ID | 2395L |
("Solvonis" or the "Company")
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company focused on developing innovative medicines for the treatment of addiction and mental health disorders, is pleased to announce that the notice of the Company's 2025 AGM and proxy form have today been posted to shareholders and can be found on the Company's website at https://solvonis.com/investor-relations/shareholder-circulars.
The Annual General Meeting will take place at 12.00 noon on 27 June 2025 at the Company's registered office being, 25 Eccleston Place, London SW1W 9NF.
In compliance with Listing Rule 9.6.1R, the notice of AGM and proxy form have today been submitted to the National Storage Mechanism and will shortly be available at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com
Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656
Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds that target high-burden neuropsychiatric conditions with significant unmet need.
The company's lead programs address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD program leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.